Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. [electronic resource]
Producer: 20131204Description: 2849-53 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Aged, 80 and over
- Antimetabolites, Antineoplastic -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Carboplatin -- administration & dosage
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Disease-Free Survival
- Female
- Glutamates -- administration & dosage
- Guanine -- administration & dosage
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Pemetrexed
- Prospective Studies
- Survival Rate
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.